Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.73 |
| ▸ | ECE1 | P42892 | 5/20 | 0.55 |
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 2/20 | 0.48 |
| ▸ | MC1R | Q01726 | 2/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762500 | 0.83 | GHSR (0.52) | GHSRHPGDSACE | |
| SCHEMBL14213192 | 0.80 | ECE1 (0.67) | ECE1HPGDSF10KMT2ACA12 | |
| SCHEMBL761165 | 0.80 | F10 (0.52) | GHSRF10 | |
| SCHEMBL762665 | 0.80 | GHSR (0.71) | GHSRECE1HPGDSF10KMT2A | |
| SCHEMBL6715572 | 0.79 | ECE1 (0.66) | ECE1HPGDSF10KMT2ACA12 | |
| Acetyltryptophanamide SCHEMBL455277 | 0.78 | ECE1 (0.68) | ECE1HPGDSF10KMT2ACA12 | |
| Acetyltryptophanamide SCHEMBL3202823 | 0.78 | ECE1 (0.68) | ECE1HPGDSF10KMT2ACA12 | |
| Acetyltryptophanamide SCHEMBL22850012 | 0.78 | ECE1 (0.68) | ECE1HPGDSF10KMT2ACA12 | |
| SCHEMBL738032 | 0.78 | GHSR (0.85) | GHSRECE1KMT2AALOX15 | |
| SCHEMBL739684 | 0.78 | GHSR (0.85) | GHSRECE1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138218-B2 | Growth hormone secretagogues | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20090131478-A1 | Growth Hormone Secretagogues | IPSEN PHARMA S.A.S. (FR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131478-A1 | Growth Hormone Secretagogues | GHSR, GHRHR, GHITM | GHSR 1/4885ECE1 1276/4885HPGDS 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.